Group items matching

in title, tags, annotations or url

This Funding Opportunity Announcement (FOA) seeks applications proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of African ancestry on the African continent to advance the important goal of global mental health equity. This funding opportunity announcement (FOA) is one of several FOAs participating in a program called, Ending Disparities in Mental Health (EDIfy-MH ). This FOA should be used when two or more collaborating sites are essential to conduct the proposed research. It is required that the Research Strategy be identical across linked collaborative U01 applications, with the exception of a short section describing the specific function of each application under "elements unique to this site." The Human Subjects section for each application should be specific to the research conducted at that site. For a linked set of collaborative U01 applications, each application must have its own Program Director/Principal Investigator (PD/PI) and the program must provide a mechanism for cross-site coordination. Applications from a single-site should be submitted under the companion FOA (PAR-MH-20-XXX).

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.

To support research projects exploring the roles of biomolecular condensates (BMCs) and their regulators in processes relevant to HIV/SIV infection, replication, latency, or pathogenesis in the context of substance use disorders. These processes could include studies exploring BMC involvement in HIV infection, HIV replication (including viral gene expression), HIV latency formation or maintenance (including chromatin structure), or HIV pathogenesis (including neurodegenerative processes). Studies could also include investigation of roles for BMCs or their regulators on host cell functions in the context of HIV infection, antiretroviral therapy, and/or exposure to addictive substances.

The goal of the K12 Institutional Career Development Program in HIV-related Heart, Lung, Blood, and Sleep (HLBS) research is to encourage institutions to develop and sustain programs that support inter-disciplinary, intensive mentored research training and career development for junior PhDs and MDs in AIDS co-morbidities as well as cell and gene therapies for HIV cure and prevention of HIV transfusion transmission.

The purpose of this Funding Opportunity Announcement (FOA) is to foster research on human long non-coding RNAs (lncRNAs) to understand their roles in controlling the gene regulatory networks underpinning normal Heart, Lung, Blood and Sleep (HLBS) homeostatic and disease processes. 

This Funding Opportunity Announcement (FOA) supports the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA).

The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.

The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance requiring clear delineation of study organization including roles and responsibilities and careful performance oversight and monitoring. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions.

The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. Also listed under R21.

To that end, grants of up to $5 million will be awarded in support of research on innovative pharmacologic interventions for Alzheimer's disease and related dementias, including clinical trials, regulatory studies for novel drugs (small molecules and biologics, including antibodies, peptides, gene therapies), repurposed drugs (existing drugs that are approved for other diseases and conditions), repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved), and natural products.

Through the program, grants of between $50,000 and $150,000 will be awarded to early-career investigators in support of novel research proposals that seek to advance the medical knowledge of migraine. Eligible research includes non-interventional clinical research, with a focus on early diagnosis and treatment, epidemiology, and Patient Reported Outcomes (PRO)/Quality of Life (QoL) measures; biomarkers for diagnosis and prognosis; and preclinical research focused on mechanism of disease (non-calcitonin gene-related peptide [CGRP]- and non-pituitary adenylate cyclase-activating polypeptide [PACAP]-related).

The ODC is offering 38 research opportunities focusing on 29 different rare diseases. This program provides a one-year grant to support research related to a rare disease represented in the 2020 Million Dollar Bike Ride. Number of awards and dollar amounts vary per disease based on fundraising totals by each disease team. Diseases included: * Adult Polyglucosan Body Disease (APBD) * Ataxia-Telangiectasia (A-T) * BPAN- A Neurodegeneration with Brain Iron Accumulation Disorder * CADASIL * Castleman Disease * Choroideremia * Congenital Hyperinsulinism (CHI) * Congenital Muscular Dystrophy (CMD) * Charcot Maire Tooth (CMT) * Cohen Syndrome (COH) * Nonsense Mutations in Cystic Fibrosis * Dyskeratosis Congenita & Telomere Biology Disorder * Fibrous Dysplasia/McCune Albright Syndrome * Fibrodysplasia Ossificans Progressiva (FOP) * Generalized Lymphatic Anomaly (GLA; a.k.a. lymphangiomatosis) and * Gorham-Stout Disease (GSD) * Glut1 Deficiency Sundrome * Inclusion Body Myositis (IBM) * Lymphangioleiomyomatosis (LAM) * Mucopolysaccharidoses (MPS) * MPS Gene Spotlight: Mucopolysaccharidosis (MPS I) * Maple Syrup Urine Disease (MSUD) * Mitochondrial Complex 1 Deficiency Disorder - NUBPL * Neuroendocrine cell Hyperplasia of Infancy (NEHI) * Niemann Pick Type C (NPC) * Pitt Hopkins Syndrome (PTHS) * RASopathies * SETBP1 Disorder * Snyder-Robinson Syndrome (SRS) * STXBP1 Encephalopathy * TBCK Syndrome

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support the development of comprehensive reference epigenomes for male and female gametes, and pre-implantation embryos after exposure to a particular environmental factor/insult.  What is envisioned is the establishment of a compendium/atlas annotating epigenetic changes during various stages of spermatogenesis, oogenesis, and pre-implantation embryo development, the identification of the affected genes, and the characterization of any resulting phenotype in the offspring.

NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate tissue- and cell-based platforms for assessing potential adverse biological consequences of somatic cell genome editing.

Through the program, grants of up to $3 million over three years will be awarded to established investigators across scientific disciplines and geographies who are positioned to make major advances in understanding the heterogeneity of systemic lupus erythematous (SLE) using highly collaborative, synergistic, and innovative approaches.

Conducting exceptional clinical research requires close collaboration between academic and industry professionals. Our year-long Clinical Research Fellowships in Oncology, Neurology, Immunology, Ophthalmology, Pulmonary Medicine and other specialty areas give fellows the crucial experience they need to transform knowledge into practice, working directly with top institutions and physicians to strengthen our commitment to developing innovative new medicines.